SeaStar Medical will report Q1 financial results on August 13, 2025, with a subsequent conference call and webcast.
Quiver AI Summary
SeaStar Medical Holding Corporation announced it will release its first quarter financial results on August 13, 2025, after market close, followed by a webcast and conference call to discuss its performance and business developments. The company specializes in treatments for critically ill patients facing organ failure, having gained FDA approval for its first commercial product, QUELIMMUNE, in 2024. This therapy addresses life-threatening acute kidney injury in pediatric patients due to sepsis. The company’s Selective Cytopheretic Device therapy has received Breakthrough Device Designation from the FDA for multiple indications, aiming for faster approval processes. SeaStar is also conducting a pivotal trial of this therapy for adult patients with severe kidney issues, impacting over 200,000 adults annually in the U.S.
Potential Positives
- SeaStar Medical is reporting its first quarter financial results on August 13, 2025, which indicates a commitment to transparency and communication with investors.
- SeaStar’s first commercial product, QUELIMMUNE, was approved by the FDA in 2024, marking a significant achievement and establishing the company as a leader in the treatment of life-threatening acute kidney injury in pediatric patients.
- The company has received Breakthrough Device Designation for its Selective Cytopheretic Device therapy for multiple therapeutic indications, potentially accelerating its market entry and improving reimbursement dynamics.
- SeaStar is actively conducting a pivotal trial for its SCD therapy in adult patients with AKI, addressing a critical healthcare need with no current effective treatments available for the estimated 200,000 affected individuals in the U.S. annually.
Potential Negatives
- Potential concern for investors as the company does not provide any financial guidance or expectations in the upcoming earnings report, leaving uncertainty about future performance.
- The announcement comes just days before the earnings call, which may suggest a lack of proactive communication about financial health and business progress.
- There is no mention of current sales figures or market performance for QUELIMMUNE, raising questions about the commercial success of their first product since FDA approval.
FAQ
When will SeaStar Medical announce its first quarter financial results?
SeaStar Medical will report its first quarter financial results on August 13, 2025, after market close.
How can I access the SeaStar Medical conference call?
To access the conference call, dial 1 (800) 715-9871 within the U.S. or 1 (646) 307-1963 from outside the U.S.
What is QUELIMMUNE(SCD-PED)?
QUELIMMUNE (SCD-PED) is SeaStar's FDA-approved treatment for life-threatening acute kidney injury in critically ill pediatric patients.
What therapeutic indications have received Breakthrough Device Designation?
SeaStar’s Selective Cytopheretic Device (SCD) therapy has received Breakthrough Device Designation for six therapeutic indications by the FDA.
What is the focus of SeaStar Medical's research?
SeaStar Medical focuses on transforming treatments for critically ill patients facing organ failure and life-threatening conditions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ICU Insider Trading Activity
$ICU insiders have traded $ICU stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ICU stock by insiders over the last 6 months:
- JENNIFER A BAIRD has made 2 purchases buying 20,000 shares for an estimated $16,989 and 0 sales.
- JOHN NEUMAN purchased 40,000 shares for an estimated $14,396
- KEVIN CHUNG (Chief Medical Officer) purchased 4,500 shares for an estimated $5,625
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Full Release
DENVER, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, August 13, 2025, and host a webcast and conference call to discuss its financial results and business progress.
|
Date/Time:
|
Wednesday, August 13, 2025, at 4:30 p.m. ET / 2:30 p.m. MT |
|
Webcast:
|
The live webcast and replay can be found
here
.
|
|
Conference ID:
|
2078693
|
|
Dial-in numbers:
|
1 (800) 715-9871 within the U.S.
1 (646) 307-1963 from outside the U.S. |
A replay of the call will be available after 7:30 pm ET and can be accessed as follows:
- The webcast replay is available
here
.
- The call replay number is 1 (609) 800-9909 and will be available through August 20, 2025.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. SeaStar’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X .
Contact:
SeaStar Investor Relations:
[email protected]
